vs
AdvanSix Inc.（ASIX）与Tempus AI, Inc.（TEM）财务数据对比。点击上方公司名可切换其他公司
Tempus AI, Inc.的季度营收约是AdvanSix Inc.的1.0倍（$367.2M vs $359.9M），AdvanSix Inc.净利率更高（-0.8% vs -14.8%，领先14.0%），Tempus AI, Inc.同比增速更快（83.0% vs 9.4%），AdvanSix Inc.自由现金流更多（$36.1M vs $-41.5M），过去两年Tempus AI, Inc.的营收复合增速更高（58.7% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Tempus AI是2015年由埃里克·莱夫科夫斯基在美国伊利诺伊州芝加哥创立的医疗科技企业，创立契机源于其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
ASIX vs TEM — 直观对比
营收规模更大
TEM
是对方的1.0倍
$359.9M
营收增速更快
TEM
高出73.6%
9.4%
净利率更高
ASIX
高出14.0%
-14.8%
自由现金流更多
ASIX
多$77.7M
$-41.5M
两年增速更快
TEM
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $367.2M |
| 净利润 | $-2.8M | $-54.2M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | -16.7% |
| 净利率 | -0.8% | -14.8% |
| 营收同比 | 9.4% | 83.0% |
| 净利润同比 | -892.9% | -316.2% |
| 每股收益（稀释后） | $-0.11 | $-0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXTEM
| Q4 25 | $359.9M | $367.2M | ||
| Q3 25 | $374.5M | $334.2M | ||
| Q2 25 | $410.0M | $314.6M | ||
| Q1 25 | $377.8M | $255.7M | ||
| Q4 24 | $329.1M | $200.7M | ||
| Q3 24 | $398.2M | $180.9M | ||
| Q2 24 | $453.5M | $166.0M | ||
| Q1 24 | $336.8M | $145.8M |
净利润ASIXTEM
| Q4 25 | $-2.8M | $-54.2M | ||
| Q3 25 | $-2.6M | $-80.0M | ||
| Q2 25 | $31.4M | $-42.8M | ||
| Q1 25 | $23.3M | $-68.0M | ||
| Q4 24 | $352.0K | $-13.0M | ||
| Q3 24 | $22.3M | $-75.8M | ||
| Q2 24 | $38.9M | $-552.2M | ||
| Q1 24 | $-17.4M | $-64.7M |
毛利率ASIXTEM
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — | ||
| Q1 24 | 0.9% | — |
营业利润率ASIXTEM
| Q4 25 | -0.7% | -16.7% | ||
| Q3 25 | -0.9% | -18.3% | ||
| Q2 25 | 7.7% | -19.6% | ||
| Q1 25 | 7.7% | -26.9% | ||
| Q4 24 | -3.9% | -25.3% | ||
| Q3 24 | 7.5% | -29.6% | ||
| Q2 24 | 11.5% | -321.4% | ||
| Q1 24 | -7.0% | -36.5% |
净利率ASIXTEM
| Q4 25 | -0.8% | -14.8% | ||
| Q3 25 | -0.7% | -23.9% | ||
| Q2 25 | 7.7% | -13.6% | ||
| Q1 25 | 6.2% | -26.6% | ||
| Q4 24 | 0.1% | -6.5% | ||
| Q3 24 | 5.6% | -41.9% | ||
| Q2 24 | 8.6% | -332.7% | ||
| Q1 24 | -5.2% | -44.4% |
每股收益（稀释后）ASIXTEM
| Q4 25 | $-0.11 | $-0.30 | ||
| Q3 25 | $-0.10 | $-0.46 | ||
| Q2 25 | $1.15 | $-0.25 | ||
| Q1 25 | $0.86 | $-0.40 | ||
| Q4 24 | $0.02 | $2.56 | ||
| Q3 24 | $0.82 | $-0.46 | ||
| Q2 24 | $1.43 | $-6.86 | ||
| Q1 24 | $-0.65 | $-1.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $604.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $491.3M |
| 总资产 | $1.7B | $2.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXTEM
| Q4 25 | $19.8M | $604.8M | ||
| Q3 25 | $23.7M | $655.9M | ||
| Q2 25 | $18.4M | $186.3M | ||
| Q1 25 | $8.3M | $151.6M | ||
| Q4 24 | $19.6M | $341.0M | ||
| Q3 24 | $17.3M | $388.0M | ||
| Q2 24 | $12.1M | $478.8M | ||
| Q1 24 | $20.6M | $79.9M |
股东权益ASIXTEM
| Q4 25 | $815.2M | $491.3M | ||
| Q3 25 | $818.2M | $507.8M | ||
| Q2 25 | $823.7M | $309.6M | ||
| Q1 25 | $794.4M | $326.2M | ||
| Q4 24 | $774.6M | $56.3M | ||
| Q3 24 | $766.4M | $53.7M | ||
| Q2 24 | $746.6M | $98.3M | ||
| Q1 24 | $713.2M | $-1.5B |
总资产ASIXTEM
| Q4 25 | $1.7B | $2.3B | ||
| Q3 25 | $1.7B | $2.3B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.6B | $926.1M | ||
| Q3 24 | $1.5B | $971.7M | ||
| Q2 24 | $1.5B | $864.6M | ||
| Q1 24 | $1.5B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $-36.8M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $-41.5M |
| 自由现金流率自由现金流/营收 | 10.0% | -11.3% |
| 资本支出强度资本支出/营收 | 7.7% | 1.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $-239.1M |
8季度趋势，按日历期对齐
经营现金流ASIXTEM
| Q4 25 | $63.7M | $-36.8M | ||
| Q3 25 | $26.6M | $-119.8M | ||
| Q2 25 | $21.1M | $44.2M | ||
| Q1 25 | $11.4M | $-105.6M | ||
| Q4 24 | $64.2M | — | ||
| Q3 24 | $57.3M | $48.7M | ||
| Q2 24 | $50.2M | $-97.1M | ||
| Q1 24 | $-36.2M | $-101.4M |
自由现金流ASIXTEM
| Q4 25 | $36.1M | $-41.5M | ||
| Q3 25 | $66.0K | $-126.5M | ||
| Q2 25 | $-7.2M | $36.6M | ||
| Q1 25 | $-22.6M | $-107.7M | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | $48.6M | ||
| Q2 24 | $16.7M | $-105.1M | ||
| Q1 24 | $-71.6M | $-107.5M |
自由现金流率ASIXTEM
| Q4 25 | 10.0% | -11.3% | ||
| Q3 25 | 0.0% | -37.9% | ||
| Q2 25 | -1.7% | 11.6% | ||
| Q1 25 | -6.0% | -42.1% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | 26.9% | ||
| Q2 24 | 3.7% | -63.3% | ||
| Q1 24 | -21.3% | -73.7% |
资本支出强度ASIXTEM
| Q4 25 | 7.7% | 1.3% | ||
| Q3 25 | 7.1% | 2.0% | ||
| Q2 25 | 6.9% | 2.4% | ||
| Q1 25 | 9.0% | 0.8% | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | 0.0% | ||
| Q2 24 | 7.4% | 4.8% | ||
| Q1 24 | 10.5% | 4.2% |
现金转化率ASIXTEM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
TEM
暂无分部数据
